Department of Integrated Traditional Chinese and Western Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Department of Nephrology, The Fifth Hospital of Xiamen, Xiamen, China.
J Ethnopharmacol. 2021 Oct 5;278:114220. doi: 10.1016/j.jep.2021.114220. Epub 2021 May 21.
Lianhuaqingwen (LHQW) is a Chinese medicine, developed from appropriate addition and reduction of combined traditional Chinese medicine (TCM) Yinqiao San and Maxing Shigan decoction. LHQW has been used in routine influenza treatment for decades and plays a role in a broad-spectrum therapy on various influenza viruses.
The therapeutic effects of LHQW in coronavirus disease 2019 (COVID-19) have not been fully elucidated. A retrospective study was conducted in patients with COVID-19 to evaluate the influence of LHQW on laboratory results related to the disease, and to provide evidence for the clinical practice of TCM.
We retrospectively collected 248 patients who met the moderate type COVID-19 diagnostic criteria, and received treatment in Tongji Hospital. Patients were divided into control (158 cases, standard treatment) and LHQW treatment (90 cases, standard treatment combined with LHQW) groups according to the different treatments administered. All laboratory data were obtained after 5-7 days' treatment.
In this study, the average patient age was 58.95 years and 131 patients were male. The two groups were comparable in demographic characteristics, symptoms, and treatment. Compared with in the control group, D-dimer and erythrocyte sedimentation rate were significantly lower in the LHQW treatment group (2.47 ± 4.67 vs. 1.68 ± 3.61; 44.47 ± 30.24 vs. 35.39 ± 27.43; both P < 0.05). Lymphocyte counts, albumin and hemoglobin levels were higher in the LHQW treatment group than those in the control group (1.00 ± 0.46 vs. 1.13 ± 0.5; 34.39 ± 5.2 vs. 35.71 ± 4.76; 127.03 ± 16.58 vs. 131.11 ± 14.66; both P < 0.05).
The study showed that LHQW significantly improved laboratory results of patients with COVID-19 and could be effectively applied alongside standard treatment of patients with moderate type COVID-19, providing preliminary clinical research evidence for the use of TCM in treatment of this disease.
连花清瘟（LHQW）是一种中药，由适当增加和减少联合中药（TCM）银翘散和麻杏石甘汤组成。LHQW 已在常规流感治疗中使用了几十年，对各种流感病毒具有广谱治疗作用。
连花清瘟治疗 2019 年冠状病毒病（COVID-19）的疗效尚未完全阐明。对 COVID-19 患者进行了回顾性研究，以评估 LHQW 对与疾病相关的实验室结果的影响，并为 TCM 的临床实践提供证据。
我们回顾性收集了符合中度 COVID-19 诊断标准并在同济医院接受治疗的 248 例患者。根据不同的治疗方法，将患者分为对照组（158 例，标准治疗）和 LHQW 治疗组（90 例，标准治疗联合 LHQW）。所有实验室数据均在治疗后 5-7 天获得。
在这项研究中，患者的平均年龄为 58.95 岁，其中 131 例为男性。两组在人口统计学特征、症状和治疗方面具有可比性。与对照组相比，LHQW 治疗组的 D-二聚体和红细胞沉降率明显更低（2.47±4.67 比 1.68±3.61；44.47±30.24 比 35.39±27.43；均 P<0.05）。LHQW 治疗组的淋巴细胞计数、白蛋白和血红蛋白水平高于对照组（1.00±0.46 比 1.13±0.5；34.39±5.2 比 35.71±4.76；127.03±16.58 比 131.11±14.66；均 P<0.05）。
研究表明，LHQW 显著改善了 COVID-19 患者的实验室结果，可与 COVID-19 中度患者的标准治疗有效联合应用，为 TCM 在该病治疗中的应用提供了初步的临床研究证据。
